Research Report on Biotech Equities -- Gilead Sciences, Exelixis, Ariad Pharma, and Novavax

Aug 19, 2016, 07:35 ET from Chelmsford Park SA

NEW YORK, August 19, 2016 /PRNewswire/ --

Companies in the Biotech industry harness cellular and biomolecular processes to develop technologies and products that help improve lives. On this morning the following equities are under evaluation: Gilead Sciences Inc. (NASDAQ: GILD), Exelixis Inc. (NASDAQ: EXEL), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), and Novavax Inc. (NASDAQ: NVAX). Learn more about these stocks by accessing their free research reports at: Gilead Sciences Foster City, California headquartered Gilead Sciences Inc.'s shares fell 0.14%, closing Thursday's trading session at $80.59. The stock recorded a trading volume of 8.99 million shares. Shares of the Company, which discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific, are trading 2.88% below their 50-day moving average. Additionally, Gilead Sciences' stock has a Relative Strength Index (RSI) of 47.59. On July 25th, 2016, Gilead Sciences announced that total revenues were $7.8 billion in Q2 2016 compared to $8.2 billion in Q2 2015. The company's non-GAAP net income, which excludes amounts related to acquisition-related, up-front collaboration, stock-based compensation and other expenses, was $4.2 billion, or $3.08 per diluted share, in the reported quarter compared to $4.8 billion, or $3.15 per diluted share, in  the comparable year ago period . On July 29th, 2016, research firm Argus downgraded the Company's stock rating from 'Buy' to 'Hold'. Free research report on GILD is available at: Exelixis On Thursday, shares in South San Francisco, California headquartered Exelixis Inc. recorded a trading volume of 5.20 million shares. The stock edged 3.30% higher, ending the day at $10.97. The Company's shares have surged 28.60% in the last month, 104.28% in the previous three months, and 94.50% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 26.79% and 88.87%, respectively. Furthermore, shares of Exelixis, which engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer, have an RSI of 71.66. On August 3rd, 2016, Exelixis reported that net revenues for the quarter ended June 30th, 2016 were $36.3 million compared to $8.0 million for the comparable period in 2015. The company's net loss for the quarter ended June 30th, 2016 was ($37.0) million, or ($0.16) per share, basic, compared to ($43.4) million, or ($0.22) per share, basic, for the comparable period in 2015. On August 04th, 2016, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $10 a share to $12 a share. The complimentary research report on EXEL can be downloaded at: Ariad Pharma Cambridge, Massachusetts headquartered Ariad Pharmaceuticals Inc.'s stock finished the day 0.48% lower at $10.40 and with a total volume of 2.31 million shares traded. The Company's shares have surged 36.30% in the last one month, 35.77% in the previous three months, and 66.40% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 24.48% and 50.77%, respectively. Additionally, shares of Ariad Pharmaceuticals, which engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally, have an RSI of 73.46. On August 1st, 2016, PDL BioPharma, Inc. announced that it has funded the second tranche of $50 million to ARIAD Pharmaceuticals, which was due on the first anniversary of the closing date under the terms of the ARIAD Royalty Agreement. This agreement was entered into in July 2015, in exchange for royalties on the net revenues of Iclusig® (ponatinib).Visit us today and access our complete research report on ARIA at: Novavax Shares in Gaithersburg, Maryland headquartered Novavax Inc. ended yesterday's session 2.31% lower at $7.19. The stock recorded a trading volume of 5.58 million shares, which was above its three months average volume of 5.06 million shares. The Company's shares have advanced 40.98% in the previous three months. The stock is trading 0.19% above its 50-day moving average and 13.05% above its 200-day moving average. Moreover, shares of Novavax, which focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants, have an RSI of 48.53. On August 9th, 2016, Novavax reported a net loss of $79.4 million, or $0.29 per share, for Q2 2016 compared to a net loss of $20.6 million, or $0.08 per share, for Q2 2015. Novavax's revenue in Q2 2016 decreased 82% to $2.5 million, compared to $14.0 million for the same period in 2015. The company attributed the lower revenue of $13.6 million (under the BARDA contract) as the primary driver of the drop in revenue. Get free access to your research report on NVAX at: -- Stock Callers: Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.  SC has not been compensated; directly or indirectly; for producing or publishing this document.  PRESS RELEASE PROCEDURES: The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.   NO WARRANTY SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.  NOT AN OFFERING This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA